Accordingly, this work was designated to impregnate MSC conditioned media with a common PI3K/Akt/mTOR inhibitor, Wortmannin, to explore their combined antiproliferative effect against luminal-A breast cancer cells and to monitor their impact on PI3l/mTOR pathway. Here, MTOR is linked to breast cancer.